A multi-landing pad DNA integration platform for mammalian cell engineering

Leonid Gaidukov, Liliana Wróblewska, Brian Teague, Tom Nelson, Xin Zhang, Yan Liu, Kalpana Jagtap, Selamawit Mamo, Wen Allen Tseng, Alexis L. Lowe,

Nucleic Acids Research · 2018 · 173 citations · 39 references

DOIFull text

Open access

Concepts

TL;DR

Engineering mammalian cell lines that stably express many transgenes requires precise insertion of large amounts of heterologous DNA into well‑characterized genomic loci, but current methods are limited. To facilitate reliable large‑scale engineering of CHO cells, the authors identified 21 novel genomic sites that support stable long‑term transgene expression and constructed cell lines containing one, two, or three landing‑pad recombination sites at selected loci. The platform employs 21 validated landing pads and a highly efficient BxB1 recombinase with distinct selection markers to insert heterologous DNA, enabling simultaneous targeting of up to three sites in a single transfection. Using this system, the authors integrated up to nine copies of a monoclonal antibody (~100 kb across 21 transcriptional units) into validated loci, achieving stable, week‑long expression that increased linearly with copy number, demonstrating controllable, reproducible large‑scale DNA insertion with broad biomanufacturing potential.

Abstract

Engineering mammalian cell lines that stably express many transgenes requires the precise insertion of large amounts of heterologous DNA into well-characterized genomic loci, but current methods are limited. To facilitate reliable large-scale engineering of CHO cells, we identified 21 novel genomic sites that supported stable long-term expression of transgenes, and then constructed cell lines containing one, two or three 'landing pad' recombination sites at selected loci. By using a highly efficient BxB1 recombinase along with different selection markers at each site, we directed recombinase-mediated insertion of heterologous DNA to selected sites, including targeting all three with a single transfection. We used this method to controllably integrate up to nine copies of a monoclonal antibody, representing about 100 kb of heterologous DNA in 21 transcriptional units. Because the integration was targeted to pre-validated loci, recombinant protein expression remained stable for weeks and additional copies of the antibody cassette in the integrated payload resulted in a linear increase in antibody expression. Overall, this multi-copy site-specific integration platform allows for controllable and reproducible insertion of large amounts of DNA into stable genomic sites, which has broad applications for mammalian synthetic biology, recombinant protein production and biomanufacturing.

References

39